MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation
May 18, 2022 16:18 ET
|
MiMedx Group, Inc
Decisive, Positive Actions Taken to Stabilize and Transform MIMEDX Have Established Strong, New Foundation for Growth Company Urges Shareholders to Vote “FOR” Both Highly Qualified Director Nominees...
MIMEDX Mails Letter to Shareholders
May 16, 2022 08:00 ET
|
MiMedx Group, Inc
Highlights Successful Execution of Transformation Strategy Under CEO Tim Wright Reaffirms Commitment to Enhancing Value for ALL Shareholders Urges Shareholders to Vote “FOR” Both of MIMEDX’s...
MIMEDX Comments on Prescience Point’s False and Misleading Statements
May 09, 2022 08:00 ET
|
MiMedx Group, Inc
Cautions Shareholders Not to Let Prescience Point Unravel MIMEDX’s Transformation Urges Shareholders to Protect their Investments by Voting “FOR” Dr. Phyllis Gardner and James L. Bierman Highlights...
MIMEDX to Participate at Upcoming Investor Conferences
May 05, 2022 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., May 05, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management...
MIMEDX Announces First Quarter 2022 Operating and Financial Results
May 03, 2022 16:32 ET
|
MiMedx Group, Inc
First Quarter Net Sales of $58.9 Million Reflects Double-Digit Revenue Increase for the Third Straight Quarter in the Company's Continuing Portfolio of Products Management to Host Conference Call...
MIMEDX Comments on Prescience Point’s Recent Filing
April 29, 2022 09:09 ET
|
MiMedx Group, Inc
Shareholders Urged to Support MIMEDX Board MARIETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics...
MIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4
April 20, 2022 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., April 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report...
MIMEDX to Present Health Economics Clinical Data for EPIFIX® in Treatment of Lower Extremity Diabetic Ulcers at SAWC Spring
April 05, 2022 08:00 ET
|
MiMedx Group, Inc
Company to Sponsor Symposium and Present Three Poster Abstracts MARIETTA, Ga., April 05, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational...
MIMEDX to Present at the Canaccord Genuity Musculoskeletal Conference
March 15, 2022 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., March 15, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R....
MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
February 28, 2022 16:06 ET
|
MiMedx Group, Inc
Fourth Quarter Net Sales of $67.4 Million and Full Year 2021 Net Sales of $258.6 Million; Reflects a Double-Digit Revenue Increase in the Company's Continuing Portfolio of Products Vibrant Commercial...